α-Fetoprotein Gene Delivery to the Nasal Epithelium of Nonhuman Primates by Human Parainfluenza Viral Vectors by Zhang, Liqun et al.
Research Articles
a-Fetoprotein Gene Delivery to the Nasal Epithelium of
Nonhuman Primates by Human Parainfluenza Viral Vectors
Liqun Zhang,1 Maria P. Limberis,2 Catherine Thompson,1 Marcelo B. Antunes,3 Cindy Luongo,4
James M. Wilson,2 Peter L. Collins,4 and Raymond J. Pickles1,5
Abstract
Over the last two decades, enormous effort has been focused on developing virus-based gene delivery vectors to
target the respiratory airway epithelium as a potential treatment for cystic fibrosis (CF) lung disease. However,
amongst other problems, the efficiency of gene delivery to the differentiated airway epithelial cells of the lung
has been too low for clinical benefit. Although not a target for CF therapy, the nasal epithelium exhibits cellular
morphology and composition similar to that of the lower airways, thus representing an accessible and relevant
tissue target for evaluating novel and improved gene delivery vectors. We previously reported that replication-
competent human parainfluenza virus (PIV)-based vectors efficiently deliver the cystic fibrosis transmembrane
conductance regulator gene to sufficient numbers of cultured CF airway epithelial cells to completely correct the
bioelectric function of CF cells to normal levels, resulting in restoration of mucus transport. Here, using an in vitro
model of rhesus airway epithelium, we demonstrate that PIV mediates efficient gene transfer in rhesus epi-
thelium as in the human counterpart. Naive rhesus macaques were inoculated intranasally with a PIV vector
expressing rhesus macaque a-fetoprotein (rhAFP), and expression was monitored longitudinally. rhAFP was
detected in nasal lavage fluid and in serum samples, indicating that PIV-mediated gene transfer was effective
and that rhAFP was secreted into both mucosal and serosal compartments. Although expression was transient,
lasting up to 10 days, it paralleled virus replication, suggesting that as PIV was cleared, rhAFP expression was
lost. No adverse reactions or signs of discomfort were noted, and only mild, transient elevations of a small
number of inflammatory cytokines were measured at the peak of virus replication. In summary, rhAFP proved
suitable for monitoring in vivo gene delivery over time, and PIV vectors appear to be promising airway-specific
gene transfer vehicles that warrant further development.
Introduction
Therapeutic gene delivery to the human respiratoryepithelium has potential applications for alleviating the
consequences of inherited diseases such as cystic fibrosis (CF),
a1-antitrypsin deficiency, as well as acquired diseases such as
asthma, surfactant protein deficiencies, and chronic obstruc-
tive pulmonary disease (COPD). Attempts to deliver thera-
peutic transgenes to human ciliated airway epithelium have
been challenging largely because of the inability of the cur-
rently available vectors (e.g., lentivirus, adenovirus, adeno-
associated viral vectors, and liposomes) to deliver transgenes
to sufficient numbers of airway epithelial cells for clinical
benefit (Klink et al., 2004; Tate and Elborn, 2005). Efficient
gene transfer vectors for gene delivery to the human ciliated
airway epithelium remain highly desirable.
We have previously reported that a recombinant human
parainfluenza virus type 3 (PIV3, Respirovirus genus, Para-
myxoviridae family) infects an in vitro model of human cil-
iated airway epithelium (HAE) and specifically targets
ciliated epithelial cells (Zhang et al., 2005), the predominant
cell type in human airways (Kreda et al., 2005). Moreover,
because the cystic fibrosis transmembrane conductance reg-
ulator (CFTR) is normally expressed in ciliated cells, we used
HAE derived from subjects with CF (CF HAE) to perform
proof-of-concept studies designed to deliver CFTR to CF
ciliated cells. These studies demonstrated that PIV3-based
vectors successfully delivered CFTR to sufficient numbers of
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CF ciliated cells to completely reverse the CF phenotype to
non-CF levels, that is, transepithelial ion and fluid transport,
airway surface liquid volume regulation, and mucus trans-
port were all restored to levels measured in non-CF HAE
(Zhang et al., 2009).
PIV3 is a frequent cause of acute respiratory tract illness in
humans, especially in the pediatric population. The virus
contains a single-stranded negative-sense RNA genome of
15.5 kb (Karron and Collins, 2006). To test whether our PIV3-
based vectors were capable of delivering transgenes to the
respiratory epithelium in vivo, we chose to administer PIV3
vectors to the nasal epithelium of the rhesus macaque
(Macaca mulatta). We chose this animal model for our in vivo
studies because (1) the nasal epithelium has been used as a
relevant and well-tolerated site to test gene transfer vectors
that would subsequently be tested in the lower airways
and because (2) PIV3 infects and replicates in cultured well-
differentiated rhesus airway epithelial cells at levels similar
to those in human airway epithelial cells (present study). In
addition, the adult rhesus macaque approximates the size of
a human infant, which would be the most likely CF patient
population targeted for CFTR gene replacement.
Because no CFTR-deficient nonhuman primate model is
currently available, testing the functional consequences of
CFTR delivery to the rhesus nasal epithelium was not fea-
sible. Therefore, we chose to deliver a marker gene expressed
from PIV3 that enabled minimally invasive monitoring and
allowed longitudinal assessment of gene expression in vivo.
The marker transgene we chose to express was rhesus
a-fetoprotein (rhAFP). AFP is normally produced in large
quantity by the yolk sac and the liver only during fetal
development (Mizejewski, 2001). Normal levels of AFP in
adults are low, and AFP has no known function in healthy
adults (Ball et al., 1992). The advantages of AFP as a reporter
gene for in vivo studies are 4-fold: (1) the background level of
AFP in adult animals is close to undetectable, enabling high
sensitivity of detection; (2) expression of a species-matched
AFP gene in adults is recognized as self and, thus, is non-
immunogenic; (3) AFP is readily secreted from cells, enabling
quantification in bodily fluids without invasive procedures;
and, (4) commercial ELISA kits for human AFP are available
that cross-react with rhAFP. Species-matched AFP has pre-
viously been used to assess gene transfer in the alveolar re-
gions of baboons after adenoviral vector administration
(O’Neal et al., 2000).
Materials and Methods
Construction of recombinant PIV3 vectors expressing
two transgenes simultaneously
PIV3GFP virus in which the green fluorescent protein (GFP)
gene was inserted between the P and M genes (Zhang et al.,
2005) was used to accommodate an additional gene, either
rhAFP or CFTR, between the HN and L genes (Fig. 1A). First, a
unique EagI restriction site (positions 9375–9380) was generated
within the downstream noncoding region of the HN gene
through site-directed mutagenesis. Next, the rhesus macaque
AFP-coding sequence was amplified by RT-PCR from fetal
rhesus macaque liver RNA (a kind gift from A. Tarantal, Uni-
versity of California at Davis, Davis, CA) with the following
primer set: sense (50-CCGCGGACCATGAAGTGGGTGGAA
TCAA-30) and antisense (50-GGGCCCGTAATTTAAACTCC
CAA-30); the underlined portions represent SacII and ApaI sites,
respectively. The rhesus macaque AFP, flanked by SacII and
ApaI sites, was then inserted into a linker sequence containing
the PIV3 gene-end (GE), intergenic (IG), and gene-start (GS)
transcription signals, flanked at both ends by EagI sites. Last,
this EagI cassette was inserted into the unique EagI site in
PIV3GFP generated previously, to create PIV3GFP-AFP. Simi-
larly, the full-length human CFTR-coding sequence was cloned
in place of AFP to create PIV3GFP-CFTR. The viral genomes
were designed to be multiples of six, which is a requirement for
efficient PIV3 genome replication. The recombinant viruses
were rescued and propagated in LLC-MK2 cells (American
Type Culture Collection [ATCC], Manassas, VA), using reverse
genetics techniques as reported previously (Durbin et al., 1997).
Generation of the in vitro model of well-differentiated
human or rhesus macaque airway epithelium
The generation of human airway epithelial (HAE) cell
cultures has been described previously (Fulcher et al., 2005).
For rhesus macaque airway epithelial (rhMAE) cell cultures,
macaque tracheal epithelial cells were isolated from rhesus
macaque tracheas (obtained from the Gene Therapy Program
at the University of Pennsylvania, Philadelphia, PA), by
adapting the protocol for HAE cultures (Fulcher et al., 2005).
Briefly, fresh isolated cells were seeded on collagen IV-coated
permeable membrane supports (Millicells, 12 mm in diame-
ter, 0.4-mm pore size; Millipore, Bedford, MA) at a density of
200,000 cells per culture insert. On reaching confluency (2–3
days), cultures were allowed to differentiate under an air–
liquid interface (ALI), and reached the mature and well-
ciliated phenotype (>50% ciliated cells) in 4–6 weeks. For
histological examination, HAE and rhMAE cells were fixed
in 4% paraformaldehyde (PFA), paraffin embedded, sec-
tioned (thickness, 5mm), and stained with hematoxylin and
eosin (H&E).
Intranasal inoculations of PIV3 vectors into rhesus
macaque and evaluations for transgene expression
Experiments with rhesus macaques were carried out ac-
cording to protocols approved by the Institutional Animal
Care and Use Committee of the University of Pennsylvania.
Two healthy adult rhesus macaques, weighing 9.8 and 8.3
kg, respectively, were first confirmed to be seronegative for
PIV3. The animals were anesthetized with a mixture of ke-
tamine (10–15 mg/kg) and dexmedetomidine (0.5–1.0 mg/
kg) injected intramuscularly. The macaques were then in-
tubated with an endotracheal tube to maintain a patent air-
way. A pediatric Foley catheter was placed in one of the
nares and, once in place, the balloon was inflated with air
and the catheter pulled back until resistance was achieved.
The naris opening was also blocked at the proximal side
with another pediatric Foley catheter after inflation of the
balloon. Approximately 2 ml of viral solution (diluted with
phosphate-buffered saline [PBS]) was infused into the nasal
cavity via a catheter and allowed to remain there for 5–7 min.
Each macaque received PIV3GFP-AFP or PIV3GFP-CFTR at
a dose of 4 ml of viral vector (1106 plaque-forming units
[PFU]/ml; 2 ml per naris). The macaques were observed and
monitored daily for signs of rhinorrhea, sneezing, loss of
appetite, and change in body temperature and weight. To
detect secreted AFP after PIV3GFP-AFP vector inoculation,
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nasal lavage fluid (NLF) and serum samples were harvested
at 2, 4, 8, 10, 14, 17, and 21 days postinoculation. To collect
NLF, macaques were sedated and intubated as during viral
inoculation; one pediatric Foley catheter was used to block
the back end of the nasal cavity; 5 ml of PBS (per naris) was
used to flush the nasal cavity, collected, aliquoted, and
stored at 808C. Viruses present in NLF were titrated by
plaque assay on LLC-MK2 cells. A 4-ml blood sample per
macaque was collected from the femoral vein at the same
time points; and sera were aliquoted and stored at 808C.
Results and Discussion
To construct PIV3 incorporating the rhesus macaque AFP
gene (GenBank accession number XM_001103873.1), the AFP
cDNA was cloned from fetal rhesus macaque liver RNA and
inserted between the HN and L genes in the recombinant
PIV3GFP backbone as an extra gene under the control of a
set of PIV3 gene-end (GE), intergenic (IG), and gene-start
(GS) regulatory sequences (Fig. 1A and Materials and
Methods). This vector was designated PIV3GFP-AFP. A
control PIV3 vector expressing CFTR (PIV3GFP-CFTR) was
constructed in which the human CFTR gene was inserted
into the viral genome in place of the rhAFP gene. Thus, both
PIV3 vectors expressed two foreign genes simultaneously,
that is, the 717-nucleotide GFP gene and either the 1830-
nucleotide rhAFP gene or the 4443-nucleotide CFTR gene.
Each foreign gene was expressed as a separate poly-
adenylated mRNA. The presence of these foreign genes in-
creased the nucleotide length of the PIV3 genome from
15,426 to 18,055 nucleotides (an increase of 17%, PIV3GFP-
AFP) or to 20,677 nucleotides (an increase of 34%, PIV3GPF-
CFTR). Both viruses were readily rescued in LLC-MK2 cells
and amplified by passage (Durbin et al., 1997). Titers gener-
ated and plaqued on LLC-MK2 cells indicated that PIV3GFP-
AFP and PIV3GFP-CFTR replicated to similar levels as
PIV3GFP virus (Zhang et al., 2005) but that PIV3GFP-CFTR
was attenuated by 10-fold as previously reported (Zhang




efficiency in human and
macaque ciliated airway
epithelium in vitro. (A)
Schematic of the genomic
structures of PIV3GFP-AFP
and PIV3GFP-CFTR vec-
tors. The linear wild-type
PIV3 genome is shown
with virus-encoded genes
(open boxes) labeled, as
well as the extragenic 30
leader (le) and 50 trailer (tr)
sequences. The GFP gene
was inserted between the
P and M genes. The rhesus
macaque AFP or human
CFTR gene (each rep-
resented as a shaded rect-
angle, with the ATG
initiation and TAA/G ter-
mination codons indicat-
ed), together with the PIV3
gene-end (GE), intergenic
(IG), and gene-start (GS)
transcription signals, was
inserted into a unique EagI
restriction site (*EagI, posi-
tions 9375–9380, indicated
by a blue vertical line) with-
in the downstream noncod-
ing region of the HN gene.
This places the rhAFP- or
CFTR-coding sequence as
a separate, added gene that
is expressed as a sepa-
rate mRNA. Sequences are
shown as positive-sense. (B) Photomicrographs of hematoxylin and eosin (H&E)-stained cross-sections of well-differentiated
ciliated airway epithelial cell cultures from (panel i) human (HAE) or (panel ii) rhesus macaque (rhMAE). Note the abundance of
ciliated cells facing the lumenal surface for cultures from both species. Scale bar: 30mm. (C) Fluorescence en face photomicro-
graphs showing GFP expression in HAE (panels i and ii) or rhMAE (panels iii and iv) 2 days after inoculation of the apical
surfaces with 106 PFU (MOI, 3) of PIV3GFP-AFP (panels i and iii) or PIV3GFP-CFTR (panels ii and iv). Scale bar: 200mm.
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et al., 2009) (PIV3GFP, 4.1107 PFU/ml; PIV3GFP-AFP,
1.3107 PFU/ml; and PIV3GFP-CFTR, 2.12106 PFU/ml).
To determine whether PIV3 vectors infect human and
rhesus differentiated airway epithelial cells similarly, we
inoculated in vitro cultures of HAE and rhesus macaque
airway epithelial cells (rhMAE) in parallel and quantified
infection efficiency and the secretion of rhAFP in both the
apical (mucosal) and basolateral (serosal) compartments.
Rhesus macaque airway epithelial (rhMAE) cell cultures
were generated according to protocols similar to those for
HAE (see Materials and Methods). Histological examination
showed that the rhMAE cultures exhibited a pseudostratified
mucociliary epithelium (Fig. 1B, panel ii) that was indistin-
guishable from HAE (Fig. 1B, panel i). Ciliated cells
accounted for *60–80% of the lumenal surface epithelial
cells in rhMAE and exhibited mucus production and trans-
port on the lumenal surface as previously reported for HAE
(Zhang et al., 2009).
To assess the extent of PIV-mediated gene transfer, the
apical surface of HAE and rhMAE cultures was inoculated
with PIV3GFP-AFP or PIV3GFP-CFTR at equal titer (1106
PFU per 12-mm diameter culture insert; multiplicity of in-
fection [MOI], &3). GFP-positive cells were visualized with
an inverted fluorescence microscope (DMIRB; Leica Micro-
systems, Wetzlar, Germany). Representative en face photo-
micrographs of GFP-positive cells 2 days postinoculation are
shown in Fig. 1C, demonstrating that both PIV3 vectors ef-
ficiently transduced HAE and rhMAE. Ciliated cells were the
target cell type for PIV3 in both HAE and rhMAE infections
(data not shown). The percentage of GFP-positive cells in
HAE and rhMAE over time was quantified with ImageJ
software (National Institutes of Health [NIH], Bethesda, MD)
(Fig. 2A and B, respectively). Unexpectedly, this revealed a
difference between HAE and rhMAE in the kinetics of GFP
transduction after PIV3 inoculation. For HAE (Fig. 2A), the
number of GFP-positive cells after inoculation with
PIV3GFP-AFP or PIV3GFP-CFTR peaked at 2 days postin-
oculation, and then gradually decreased to a low, steady
level 10 days postinoculation. This was the expected result
given our previous demonstration that PIV3-infected ciliated
cells are lost from the epithelium by a process of accelerated
ciliated cell shedding (Zhang et al., 2009). At all time points,
PIV3GFP-AFP infected more ciliated cells compared with
PIV3GFP-CFTR; a finding likely due to the increased rate of
replication for PIV3GFP-AFP because of its smaller transgene
insert. In contrast to the HAE data, the extent of ciliated cell
infection (GFP-positive cells) in rhMAE was more gradual
and infection continued to increase for the duration of the
experiment (17 days) (Fig. 2B). The prolonged infection of
rhMAE by PIV3 vectors was observed with cultures derived
from multiple individual animals (data not shown).
Infection by PIV3GFP-AFP was more efficient than by
PIV3GFP-CFTR (compare Fig. 1C, panel i vs. ii and panel iii
vs. iv), even though the cultures were inoculated with equal
titers. Furthermore, the viral titers measured on the lumenal
surface of HAE at 48 hr postinoculation with PIV3GFP-AFP
(7.65 log10 PFU/ml) were significantly higher than those
for PIV3GFP-CFTR (6.39 log10 PFU/ml), suggesting that
PIV3GFP-AFP replicated 10-fold more efficiently than
PIV3GFP-CFTR. These observations suggest that the smaller
size of the AFP transgene insert, that is, 1.8 kb for the AFP
gene (17% of PIV3 genome length) versus 4.4 kb for the
CFTR gene (35% of PIV genome length), accounted for this
difference in replication kinetics. The finding that larger in-
sertions into the PIV3 genome attenuate viral growth in vivo
is consistent with previous reports (Skiadopoulos et al., 2000,
2002; Zhang et al., 2009) and may be further exploited to
generate more attenuated vectors for future applications.
FIG. 2. Quantification of
PIV3 vector-mediated trans-
duction in vitro. The apical sur-
face of (A) HAE and (B) rhMAE
was inoculated with PIV3GFP-
AFP or PIV3GFP-CFTR as de-
scribed in Fig. 1C; and the per-
centages of GFP-positive cells
were quantified with ImageJ
software (NIH). Both apical
and basolateral supernatants
from PIV3GFP-AFP-transduced
(C) HAE and (D) rhMAE cul-
tures were harvested over time
and AFP concentrations (ng/
cm2) are shown. Error bars rep-
resent the standard deviation
(SD) (n¼ 6).
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To measure PIV3-mediated rhAFP gene transfer longitudi-
nally in airway cultures, we collected apical washes (volume,
0.3 ml) and basolateral medium (1 ml) from PIV3GFP-AFP-
infected HAE and rhMAE every 24 hr for 17 days. The con-
centration of rhAFP in these samples was quantified with a
commercial human AFP ELISA kit (Quantikine DAFP00; R&D
Systems, Minneapolis, MN), and total secreted rhAFP was
calculated by adjusting to the respective volume (apical, 0.3
ml; basolateral, 1 ml) and expressed as nanograms per square
centimeter of epithelium (Fig. 2C and D). Although rhAFP was
readily detected in the apical and basolateral compartments of
both HAE and rhMAE, significantly more rhAFP was secreted
from rhMAE (Fig. 2D) than from HAE (Fig. 2C) both in terms
of the total amount and the amount secreted into the apical
compartment. Secretion of rhAFP into the basolateral com-
partment of rhMAE cultures approximated the levels of rhAFP
secretion into the basolateral compartment of HAE despite
fewer ciliated cells infected. However, for rhMAE but not
HAE, rhAFP was secreted at 5-fold higher levels into the apical
compared with the basolateral compartment. PIV3GFP-CFTR
failed to increase rhAFP above the limit of detection in apical
or basolateral compartments of either HAE or rhMAE (data
not shown).
The duration of rhAFP secretion in HAE and rhMAE was
consistent with the quantification of GFP-positive cells in
each of these culture types, with HAE ciliated cell infection
and rhAFP secretion being transient and peaking at 2 or 3
days postinoculation whereas ciliated cell infection and
rhAFP secretion from rhMAE remained high throughout the
experiment (Fig. 2B). At present, we have no explanation for
the slower and prolonged PIV3 infection in rhMAE com-
pared with HAE. It is possible that, in this in vitro model,
appropriate innate antiviral responses of macaque epithelial
cells to human PIV3 infection are less effective. These in vitro
data suggest that PIV3GFP-AFP transduction in vivo would
result in rhAFP secretion into both mucosal and serosal
compartments, thus enabling rhAFP measurements in both
airway lumenal lavage and serum, respectively.
To investigate PIV3 vector-mediated gene transfer to
rhesus macaque airways in vivo, we delivered our vectors to
the nasal epithelium of adult rhesus macaques. This was
done for two reasons: (1) the nasal epithelium is an easily
accessible site for vector administration and the harvesting of
samples, using noninvasive procedures; and (2) the human
nasal epithelium of patients with CF has proven to be a ro-
bust model for feasibility studies to deliver CFTR to the CF
airway epithelium (Knowles et al., 1981; Boucher et al., 1994;
Flotte et al., 2003; Roxo-Rosa et al., 2006).
Two adult rhesus macaques (weight, 9.8 and 8.3 kg) were
confirmed to be seronegative for PIV3 before the onset of the
experiment. One animal was inoculated intranasally with
4 ml of PIV3GFP-AFP (106 PFU/ml) and the other received
the same dose of control vector, PIV3GFP-CFTR. Both nares
from an individual animal were inoculated with one virus
type (2 ml/naris). This viral dose (4106 PFU/macaque) is
relatively low in comparison with doses used in previous
work involving Sendai virus inoculation of mouse nasal
epithelium (1–7107 PFU in a 100-ml volume) (Ban et al.,
2007; Ferrari et al., 2007). The inoculate was administered to
the animals under sedation; two pediatric Foley balloon
catheters were used to plug the proximal and distal ends of
the nasal passages, enabling retention of vector in defined
regions of the respiratory epithelium for 5 min. We have
previously shown that as little as a 5-min exposure time of
PIV3 to the apical surface of HAE results in approximately
80% of the maximal transduction achieved after a 2-hr in-
cubation time (Zhang et al., 2009). To harvest samples for
evaluation of vector replication rates and transgene expres-
sion, 5 ml of nasal lavage fluid (NLF in PBS) and 4 ml of
serum per macaque were collected at 2, 4, 8, 10, 14, 17, and
21 days postinoculation. During this time period, with either
PIV3 vector, there were no clinical indications of disease
FIG. 3. PIV3 vector-mediated
gene expression in macaque nasal
airways is efficient and transient.
Shown are viral titers in nasal la-
vage fluid (NLF) obtained from a
rhesus macaque inoculated intra-
nasally with 4106 PFU of either
PIV3GFP-AFP (A) or PIV3GFP-
CFTR (B). Samples were harvested
at intervals from 2 to 21 days
postinoculation. AFP concentra-
tions present in NLF (C) or sera
(D) were quantified by ELISA, and
normalized by the amount of total
protein present in each sample.
Dashed line in (D) represents the
baseline AFP level detected in se-
rum obtained from the animal in-
oculated with PIV3GFP-CFTR.
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including onset of fever, weight loss, or abnormal nasal
discharge.
Viral titers in NLF were determined by a standard plaque
assay (Durbin et al., 1997). Evaluation of viral titers in sera
was not performed as PIV3 does not shed into the basolateral
compartment of HAE or into the sera of humans infected
with PIV3 (Zhang et al., 2005; Karron and Collins, 2006).
PIV3 was detected in NLF from both animals between 2 and
10 days postinoculation (Fig. 3A and B). Viral titers re-
presented production of progeny virus, not residual inocula,
because little or no virus was detected before 2 days post-
inoculation (Fig. 3A and B). The growth kinetics for both
vectors showed similar peak titers (*104 PFU/ml) at 4–8
days, with undetectable viral titers by 14 days postinocula-
tion. However, some differences between virus growth ki-
netics were noted. PIV3GFP-CFTR reached peak titers later
than PIV3GFP-AFP (8 vs. 4 days postinoculation, respec-
tively), suggesting that the PIV3GFP-CFTR vector was
attenuated compared with PIV3GFP-AFP in vivo. These data
are consistent with the in vitro results in HAE and rhMAE
(Fig. 2A and B). Furthermore, titers of PIV3GFP-CFTR re-
mained high at 10 days postinoculation whereas those for
PIV3GFP-AFP were almost undetectable on day 10 postin-
oculation. We propose that the longer period of virus
production with PIV3GFP-CFTR is related to attenuated
shedding of infected ciliated cells. We have previously
shown that human ciliated cells are shed less rapidly when
infected with PIV3CFTR versus PIV3GFP, presumably be-
cause of the 10-fold reduction in virus replication seen with
the larger insert (Zhang et al., 2009).
The concentrations of rhAFP in the NLF and serum were
quantified by ELISA. Although PIV3GFP-CFTR inoculation
did not increase rhAFP in the NLF or sera beyond the low
baseline levels (data not shown), rhAFP was detected in the
NLF and serum from the PIV3GFP-AFP-inoculated ma-
caque (Fig. 3C and D). Significant rhAFP was detected in
NLF obtained from both nostrils 4 and 8 days postinocu-
lation (Fig. 3C). Considering the brief period of nasal
flushing during NLF collection, the detection of rhAFP in
NLF samples indicated significant PIV-mediated gene de-
livery to the nasal epithelium. Serum rhAFP, a result of
rhAFP being secreted into the basolateral compartments of
the nasal epithelium and subsequent systemic distribution,
was detected 4 to 14 days postinoculation, with a peak in
expression at 8 days postinoculation. The lower levels of
rhAFP in the serum compared with those in the NLF are
likely due to the significant dilution of rhAFP into the sys-
temic circulation.
FIG. 4. Intranasal inoculation
of PIV3 vectors in macaque
caused minimal and transient
inflammatory responses. The
NLF and serum samples ob-
tained on the indicated days after
PIV3GFP-AFP (black bars) or
PIV3GFP-CFTR (gray bars) in-
oculation were assayed for the
presence of 11 cytokines/
chemokines (IL-1b, IL-6, IL-8,
MCP-1, MIP-1a, TNF-a, RANTES,
IP-10, IL-13, IFN-g, and IL-2) us-
ing macaque-specific Luminex
multiplex assays (Upstate Flex
kits; Millipore): NLF (left), serum
(right). Only those cytokines/
chemokines with values above
background levels are presented.
Values from NLF are the average
of the left and right nares.
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Interestingly, the transient expression of rhAFP in the NLF
and serum mirrored the rhAFP quantification in vitro (Fig. 2B
vs. D). Although it is tempting to speculate that similar host
defenses are responsible for the transient nature of PIV3-
mediated gene delivery in vitro and in vivo, that is, ciliated
cell shedding, it is likely that other host factors in vivo (e.g.,
infiltrating inflammatory cells) also result in clearance of the
virus and thus termination of rhAFP gene expression. To
determine the extent of inflammatory mediator production
induced by PIV3 vector transduction, we assayed for select
cytokines/chemokines in the NLF and serum samples over
time, using Luminex multiplex bead-based technology (Up-
state flex kits; Millipore). Eleven macaque-specific analytes
were quantified including interleukin (IL)-1b, IL-6, IL-8,
monocyte chemotactic protein (MCP)-1, macrophage in-
flammatory protein (MIP)-1a, tumor necrosis factor (TNF)-a,
RANTES (regulated on activation, normal T-cell expressed
and secreted), inflammatory protein (IP)-10, IL-13, interferon
(IFN)-g, and IL-2. Only IL-6, IL-8, and RANTES were found
to be modestly elevated in NLF (Fig. 4, left), whereas other
analytes did not increase above baseline levels (data not
shown). Interestingly, IL-8 levels in the NLF of the PIV3GFP-
AFP-inoculated macaque were higher than for the PIV3GFP-
CFTR-inoculated macaque, whereas more RANTES was
detected in the macaque inoculated with the PIV3GFP-CFTR
vector compared with the PIV3GFP-AFP vector. In serum
samples, only IL-8, MCP-1, and TNF-a were elevated, with
other analytes not increased above baseline (Fig. 4, right).
Thus, intranasal inoculation of macaques with PIV3 vectors
was mildly inflammatory and the kinetics of inflammatory
mediator production mirrored that of viral titers.
In summary, we show that PIV3 vectors mediate detect-
able delivery and expression of a marker transgene to in vitro
and in vivo models of rhesus airway epithelium. Although
the duration of gene expression was transient, these studies
demonstrate the usefulness of our in vitro and in vivo ma-
caque models for assessing the ability of PIV3 to deliver
genes to the respiratory epithelium. Future studies to test
PIV3 vectors that have been attenuated for replication or
engineered to remove cytotoxic and immunogenic glyco-
proteins from the virus genome will determine whether such
vectors can improve the duration of gene expression (Murphy
and Collins, 2002; Ferrari et al., 2007). We demonstrated that
the dose of PIV3 vectors used in our studies was effective at
conferring measurable gene expression in vivo and did not
cause any major adverse reactions in the animals. Im-
portantly, we showed the utility of the secretory gene AFP as
an ideal reporter transgene suitable for long-term in vitro and
in vivo studies that require high sensitivity of transgene de-
tection, thus eliminating the need to sacrifice treated animals
for gene expression assays. This study establishes a platform
for comparison of vector-mediated gene delivery using
in vitro and in vivo models, and suggests that additional
modifications of PIV3 vectors will be required for future gene
delivery applications for the ciliated airway epithelium.
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